This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Transcatheter aorticvalve replacement (TAVR) is the standard treatment for severe aortic stenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. had thrombus at any aorticvalve complex.
The optimal management of concomitant chronic obstructive coronary artery disease (CAD) in transcatheter aorticvalve replacement (TAVR) recipients remains a debated topic. While some advocate for pre-TAVR percutaneous coronary intervention, others adopt an expectant approach. Original article: Persits I et al.
How do mortality and morbidity compare after valve-in-valve (ViV) transcatheter aorticvalve replacement (TAVR) versus redo surgical aorticvalve replacement (SAVR) for intervention for a failed bioprosthetic SAVR?
What is the 5-year incidence of valve reintervention after self-expanding CoreValve/Evolut transcatheter aorticvalve replacement (TAVR) versus surgical aorticvalve replacement (SAVR)?
The Heart Valve Collaboratory has proposed a framework to standardize best practices for using multimodality imaging in transcatheter valve failure (TVF) following transcatheter aorticvalve replacement (TAVR), in a State-of-the-Art Review.
Transcatheter aorticvalve replacement (TAVR) is a relatively new treatment method for aortic stenosis (AS) and has been demonstrated to be suitable for patients with varying risk levels.
The goal of the NOTION trial was to compare outcomes after transcatheter aorticvalve replacement (TAVR) versus surgical aorticvalve replacement (SAVR) in unselected patients with severe degenerative aortic stenosis.
The goal of the EARLY TAVR trial was to evaluate transcatheter aorticvalve replacement (TAVR) compared with clinical surveillance among patients with asymptomatic severe aortic stenosis (stage C aortic stenosis).
What are the national trends in utilization of leadless pacemaker implantation following transcatheter aorticvalve replacement (TAVR) and its performance compared with transvenous pacemakers?
What are the hemodynamic and clinical outcomes after transcatheter aorticvalve replacement (TAVR) and surgical aorticvalve replacement (SAVR) among patients with severe aortic stenosis (AS) and a small aortic annulus?
The goal of the VIVA trial was to evaluate transcatheter aorticvalve replacement (TAVR) compared with surgical aorticvalve replacement (SAVR) among patients with severe aortic stenosis and a small aortic annulus.
What are outcomes among patients younger than 65 years who received transcatheter aorticvalve replacement (TAVR) using a balloon-expandable valve compared to patients aged 65-80 years?
The goal of the TAVR UNLOAD trial was to evaluate transcatheter aorticvalve replacement (TAVR) compared with clinical surveillance among patients with chronic systolic heart failure and moderate aortic stenosis (stage B aortic stenosis).
In light of the growing number of patients undergoing transcatheter aorticvalve replacement (TAVR), there is an increasing demand for data regarding the management of failed TAVR procedures, including the possibility of a repeat TAVR intervention. vs. 4.0%, p=0.36) or one year (17.5% vs. 3.3%, p=0.18).
What is the relationship between diffusion-weighted magnetic resonance imaging (DW-MRI) total lesion number (TLN), individual lesion volume (ILV), and total lesion volume (TLV) with clinical stroke outcomes after transcatheter aorticvalve replacement (TAVR)?
What is the effect of the time interval between transcatheter aorticvalve replacement (TAVR) and noncardiac surgery (NCS) (Δt) on the perioperative risk of major adverse events (MAEs)?
Two separate late-breaking clinical trials – EARLY TAVR and EVOLVED – presented at TCT 2024 explore whether early aorticvalve intervention improves outcomes in patients with asymptomatic aortic stenosis (AS).
TAVR was found to bring no increased risks and was associated with substantially decreased rates of death or stroke at one year in low-risk patients, compared with surgical aorticvalve replacement (SAVR), according to results from the DEDICATE-DZHK6 study presented during a Late-Breaking Clinical Trial session at ACC.24
Among patients undergoing transcatheter aorticvalve replacement (TAVR) with a balloon-expandable valve (BEV), what are the 3-year clinical outcomes associated with a small (20 mm) compared to a larger (≥23 mm) device, and is there a relationship between the discharge echocardiographic (echo) mean gradient (MG) and measured or predicted thresholds (..)
The following are key points to remember from a state-of-the-art guide to transcatheter aorticvalve (TAV) design and systematic planning for a redo-TAV (TAV-in-TAV) procedure.
What are the contemporary characteristics, trends, and outcomes of intravascular lithotripsy (IVL)-assisted transfemoral (TF) transcatheter aorticvalve replacement (TAVR) in the United States?
Is there a relationship between site-level volumes and outcomes for transcatheter aorticvalve replacement (TAVR) and mitral transcatheter edge-to-edge repair (MTEER)?
Seven studies showed that TAVR patients had a similar 1-year stroke risk to SAVR patients (OR 0.92, 95% CI 0.64 In the TIA case, there was no evidence of a significant difference between TAVR and SAVR in the risk of having a transient ischemic attack within 30 days following surgery (OR 0.93, 95% CI 0.24 to 1.17, p=0.30, I2 3%).
TAVR in heart failure. ABSTRACT Patients with severe aortic stenosis (AS) may develop heart failure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes. The prognostic covariates and optimal timing of TAVR in patients with less than severe AS remain unclear.
In women with symptomatic, severe aortic stenosis (AS), TAVR with the balloon-expandable valve was superior to surgical aorticvalve replacement in terms of the composite rate of death, stroke and rehospitalization at one-year follow-up, according to a pooled analysis of patient-level data from RHEIA and PARTNER 3 trials presented at TCT 2024.
What are clinical outcomes among patients with severe aortic stenosis (AS) and coronary artery disease (CAD) undergoing surgical aorticvalve replacement (SAVR) plus revascularization versus transcatheter aorticvalve replacement (TAVR) plus percutaneous coronary intervention (PCI)?
The goal of the SOLVE-TAVI trial was to compare the safety and efficacy of the Edwards Sapien S3 valve vs. Medtronics CoreValve among patients undergoing transcatheter aorticvalve replacement (TAVR) for severe aortic stenosis.
Patients with bicuspid aorticvalves (BAV) are predisposed to the development of aortic stenosis. We performed a pairwise meta-analysis, comparing the efficacy of transcatheter aorticvalve replacement (TAVR) versus surgical aorticvalve replacement (SAVR) in patients with BAV.
Subclinical leaflet thrombosis (SLT) has raised concerns about the long-term durability and outcomes of transcatheter aorticvalve replacement (TAVR). Clinical valve thrombosis (CVT) is a rare complication after TAVR with an incidence of 0.62.8%
The EARLY TAVR trial results demonstrate that early transcatheter aorticvalve implantation in patients with asymptomatic severe aortic stenosis is superior to clinical surveillance in significantly reducing the composite primary outcome of death, stroke, or unplanned hospitalization for cardiovascular causes.
The presence of cardiac amyloidosis negatively affects the outcome of patients with aortic stenosis, these patients undergo transcatheter aorticvalve replacement (TAVR) with increasing frequency and have a significantly higher overall mortality rate than patients with aortic stenosis alone.
The goal of the PROTECTED TAVR trial was to evaluate the efficacy of intraprocedural cerebral embolic protection (CEP) in reducing strokes among patients undergoing transfemoral TAVR for aortic stenosis.
The goal of the LANDMARK trial was to evaluate transcatheter aorticvalve replacement (TAVR) with the Myval prosthesis compared with a contemporary prosthesis among patients with symptomatic severe aortic stenosis.
The goal of the SMART trial was to evaluate a self-expanding valve compared with a balloon-expandable valve among patients with aortic stenosis and a small aortic annulus undergoing treatment with transcatheter aorticvalve replacement (TAVR).
Abstract: Transcatheter aorticvalve replacement (TAVR) is an interventional procedure performed in patients with severe aortic stenosis and often required perioperative antiplatelet therapy. Most previous studies have focused on antiplatelet therapy following TAVR.
has seen a 25-fold increase in the use of TAVR, with more than 100,000 performed annually. This technique is now employed in approximately 85% of all isolated aorticvalve replacements. In the past decade, the U.S. Despite this growth, there are notable gaps in the evidence.
My patient is 59 years old, has symptomatic severe aortic stenosis (AS) with a bicuspid aorticvalve (BAV), and his proximal aorta is 3.6 He has no important comorbidities and was referred for advice as to whether he should have a surgical (SAVR) or transcatheter (TAVR) aorticvalve replacement.
Hans Gustav Hørsted Thyregod, Troels Højsgaard Jørgensen, Nikolaj Ihlemann, Daniel Andreas Steinbrüchel, Henrik Nissen, Bo Juel Kjeldsen, Petur Petursson, Ole De Backer, Peter Skov Olsen, Lars Søndergaard, Transcatheter or surgical aorticvalve implantation: 10-year outcomes of the NOTION trial, European Heart Journal , 2024;, ehae043 , [link] 2.
The diagnostic coronary angiogram identified only minimal coronary artery disease, but there was a severely calcified, ‘immobile’ aorticvalve. Aortic angiogram did not reveal aortic dissection. If you see this, you should Doppler the valve. Aorticvalve surgery as an emergency procedure.
Transcatheter aorticvalve replacement (TAVR) has emerged as the preferred treatment for older patients suffering from severe aorticvalve stenosis, surpassing the annual patient count of those opting for surgical aorticvalve replacement. years, with 56% being women. in 2007-2010 to 5.5%
Within the realm of transcatheter aorticvalve replacement (TAVR), stroke emerges as a recognized adverse event, manifesting at various stages during and after the procedure. Previous studies extensively delved into short-term incidence, trends, and clinical outcomes related to TAVR-associated stroke. at 5 years.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content